Dr. Marty Makary has stepped down from his role as commissioner of the Food and Drug Administration (FDA). This marks another high-profile exit from the Trump administration this year. President Trump praised Makary, saying, “He’s a great doctor… he’s going to do well,” when asked about his departure.
Reports suggest that Trump was dissatisfied with Makary’s performance, which may have influenced the decision. Recently, the FDA authorized fruit-flavored vapes for adults, a move that aligns with Trump’s campaign promise to bring back flavors that had been removed from the market due to health concerns.
Makary’s exit comes as he faced criticism regarding a promised review of the abortion medication mifepristone. Republican lawmakers have been pressing for changes to a rule allowing the medication to be mailed, instead of requiring in-person visits. In a recent development, the Supreme Court temporarily allowed continued access to mifepristone nationwide, despite earlier restrictions.
There are also concerns that Makary requested a delay on the FDA’s safety review of mifepristone, hoping to push it past the midterm elections. His decision to step down adds to a growing list of departures from the Trump administration, which includes former Homeland Security Secretary Kristi Noem and former Attorney General Pam Bondi.
Dr. Ofer Levy, director at Boston Children’s Hospital, shared insights on the challenges ahead for Makary’s successor. He emphasized that public health threats, like hantavirus, highlight our interconnectedness and the need for a strong response.
As healthcare continues to evolve, the leadership at the FDA will be crucial in addressing issues that directly impact public wellbeing.
Source link
